ArriVent BioPharma (AVBP) Return on Capital Employed (2024 - 2026)
ArriVent BioPharma (AVBP) posted Return on Capital Employed of 49.61% for Q1 2026, up 15.08% sequentially from 58.42% in Q4 2025, and up 1084.0% YoY from 4.19% in Q1 2025.
ArriVent BioPharma (AVBP) Return on Capital Employed (2024 - 2026) Analysis & Trends
ArriVent BioPharma has reported Return on Capital Employed for 3 years, with the latest figure at 49.61% in Q1 2026.
- Quarterly Return on Capital Employed rose 1084.0% year-over-year to 49.61% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 49.61% (up 1084.0% YoY) and the FY2025 annual result came in at 63.84%, down 1709.0% from the prior year.
- Return on Capital Employed improved to 49.61% in Q1 2026 per AVBP's latest filing, from 58.42% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 28.15% in Q2 2024 and troughed at 66.56% in Q2 2025.
- A 3-year average of 47.27% and a median of 49.61% in 2026 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed plunged 3841 bps in 2025, then soared 1084 bps in 2026.
- Over 3 years, Return on Capital Employed stood at 35.38% in 2024, then sank by 65 bps to 58.42% in 2025, then grew by 15 bps to 49.61% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 49.61%, 58.42%, and 58.75% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | -51.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51.12% |
| Mar 31, 2026 | -49.61% |
| Dec 31, 2025 | -58.42% |
| Sep 30, 2025 | -58.75% |
| Jun 30, 2025 | -66.56% |
| Mar 31, 2025 | -60.45% |
| Dec 31, 2024 | -35.38% |
| Sep 30, 2024 | -32.81% |
| Jun 30, 2024 | -28.15% |
| Mar 31, 2024 | -35.28% |